 |
|
 |
 |

Home > Company Index > Drugs > Drug Manufacturers - Other > Shire Pharmaceuticals Group plc
 |
Shire Pharmaceuticals Group plc |
 |
 |
 |
NEWS FROM THE WIRES |
 |
Before The Bell - Stock futures sag, Shire gains Aug 06 2001 04:08 AM PDT
> More WIRE STORIES about this company
PROFILE |
 |
Shire Pharmaceuticals Group does no research, but concentrates on searching for, developing, and marketing drugs. Its product roster includes treatments for cancer, metabolic diseases, central nervous system disorders, and gastroenterological ailments. Shire Pharmaceutical Group's products, which are sold worldwide, include attention deficit hyperactivity disorder treatment Adderall (a serious challenger to Novartis' ubiquitous Ritalin) and Carbatrol, a reformulation of a popular epilepsy treatment. In an effort to boost its pipeline and its geographical scope, Shire has acquired Roberts Pharmaceutical and BioChem Pharma.
COMPETITION |
 |
Eli Lilly and Company (LLY)
Novartis AG (NVS)
Pfizer Inc (PFE)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 517.60
1-Yr. Sales Growth: 28.9%
Employees: 1,023
Revenue per employee: $505,962.85
KEY PEOPLE |
 |
Rolf Stahel
CEO
Angus Russell
CFO
CONTACT INFO |
 |
Hampshire International Business Park, Chineham
Basingstoke Hampshire RG24 8EP, United Kingdom
Phone: 44-1256-894-000
Fax: 44-1256-894-708
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |